Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 262

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

Kumar, Shaji K, Berdeja, Jesus G, Niesvizky, Ruben, Lonial, Sagar, Laubach, Jacob P, Hamadani, Mehdi, Stewart, A Keith, Hari, Parameswaran, Roy, Vivek, Vescio, Robert, Kaufman, Jonathan L, Berg, Deborah, Liao, Eileen, Di Bacco, Alessandra, Estevam, Jose, Gupta, Neeraj, Hui, Ai-Min, Rajkumar, Vincent, Richardson, Paul G · 2014 · The Lancet Oncology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(14)71125-8

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 3

  1. Kumar, 2013, Phase 2 trial of single agent MLN9708 in patients with relapsed multiple myeloma not refractory to bortezomib, Blood, 122, 1944
  2. Sonneveld, 2012, Carfilzomib combined with thalidomide and dexamethasone (CTD) is an highly effective induction and consolidation treatment in newly diagnosed patients with multiple myeloma (MM) who are transplant candidate, Blood, 120, 333, 10.1182/blood.V120.21.333.333 · doi:10.1182/blood.v120.21.333.333
  3. Reeder, 2013, A phase I/II trial of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma: final results of MTD expansion cohort, Blood, 122, 3179, 10.1182/blood.V122.21.3179.3179 · doi:10.1182/blood.v122.21.3179.3179

Cited by

See all 262

Metadata

Authors
Kumar, S. K., Berdeja, J. G., Niesvizky, R., Lonial, S., Laubach, J. P., Hamadani, M., Stewart, A. K., Hari, P., Roy, V., Vescio, R., Kaufman, J. L., Berg, D., Liao, E., Di Bacco, A., Estevam, J., Gupta, N., Hui, A.-M., Rajkumar, V., & Richardson, P. G.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2014-12
Volume
15
Issue
13
Pages
1503-1512
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2095384810
Cited by
262
References
27
FWCI
24.49
Type
journal article
Language
en
Update notices
erratum (2019-07-01)
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(14)71125-8
The paper
Kumar, S. K., Berdeja, J. G., Niesvizky, R., Lonial, S., Laubach, J. P., Hamadani, M., Stewart, A. K., Hari, P., Roy, V., Vescio, R., Kaufman, J. L., Berg, D., Liao, E., Di Bacco, A., Estevam, J., Gupta, N., Hui, A.-M., Rajkumar, V., & Richardson, P. G. (2014). Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(14)71125-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.